The latest price target for Mind Medicine (NASDAQ:MNMD) was reported by Canaccord Genuity on September 16, 2024. The analyst firm set a price target for $14.00 expecting MNMD to rise to within 12 months (a possible 128.39% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Mind Medicine (NASDAQ:MNMD) was provided by Canaccord Genuity, and Mind Medicine maintained their buy rating.

There is no last upgrade for Mind Medicine

There is no last downgrade for Mind Medicine.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mind Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mind Medicine was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Mind Medicine (MNMD) rating was a maintained with a price target of $16.00 to $14.00. The current price Mind Medicine (MNMD) is trading at is $6.13, which is out of the analyst’s predicted range.